High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
about
When prostate cancer remains undetectable: The dilemmaRole of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer[Prostate biopsy: Procedure in the clinical routine].A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.Focal therapy in the management of localized prostate cancer.Critical review of prostate cancer predictive toolsRepeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean menMagnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.Beyond diagnosis: evolving prostate biopsy in the era of focal therapy.Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study.Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancerSaturation biopsy for detecting and characterizing prostate cancer.A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue.Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.Effect of the number of biopsy cores on prostate cancer detection and staging.Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancerManagement of rising prostate-specific antigen after a negative biopsy.Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience.Optimising repeat prostate biopsy decisions and procedures.The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy.Random biopsy: when, how many and where to take the cores?Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies.Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy.History of malignancy is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.Community-based prostate cancer screening in Japan: predicting factors for positive repeat biopsy.Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection.A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomyDetecting Prostate CancerAssessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsiesPathological Correlation between Number of Biopsies and Radical Surgery: Does It Make a Difference to Final Pathology?Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.Evaluation of MRI/Ultrasound Fusion-Guided Prostate Biopsy Using Transrectal and Transperineal Approaches.Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
P2860
Q26795515-95867340-FE62-47D3-A241-33FB71BBCC88Q26998938-F374FEBB-D24F-4223-A883-AA72E2BF5B13Q30315859-0A64B746-92DD-4E91-827E-077730261147Q33642692-1573960A-4A86-4EC0-845E-6F62C358FF83Q33790382-0385D2C0-C74C-445E-9736-371FDF5072B5Q34104562-F3A5CD2E-8291-4B7F-8023-E700D09BA069Q34608622-8B240B2F-E891-4C0D-9D38-EFEF96E69D29Q35141766-CF2F1DB0-0C42-4C14-A02D-94A1C256C4CCQ35354750-72CA9BC1-7907-49A9-99AD-F7262DF64EA4Q35550202-CCEAA236-4DAD-45C0-AE20-1E8F1AF4F134Q35665891-506BE7DD-7B99-4C0C-BC03-0298DBDAA257Q36264683-A39F4581-3F85-4ABF-8C9A-34C29D27E380Q36788576-1DBA3029-3140-4494-B5A8-21AB665C2FABQ36790412-4187BA07-AB9A-4895-866B-C5BD968C13A8Q37381526-A96B44BB-32A0-4EAF-89BA-402934084B80Q37707378-13994253-8CC7-47EA-AD8F-6C6670612635Q37709638-789779CD-9C25-4720-925B-A8C92B29F43AQ37846119-67420EA6-BB96-401D-9624-609BFB8EDE11Q37892629-000CC61D-5DCB-4808-9336-5ABCC9E92BEBQ37970859-5230D39C-F689-4584-A70B-F172E085A953Q38165242-12C0B620-2F0F-4B37-8AA5-F1F5006D6804Q38218443-5FD8DD49-D5E8-4F29-B100-49E19FA97593Q38219598-2B36F321-98CB-47B2-AF29-BC71831B2DD0Q39477975-8F2B58EF-1385-49C8-BDAA-4A75234E01E7Q39564842-9E3B34D2-A9C2-417B-B017-564F81E2F87FQ39864757-AB720894-6999-4162-9E7B-C7593FC50082Q39877029-AF910CFC-1B60-476E-B0E1-800F5E9A16F1Q39879600-D244C521-B94F-4952-8172-665BC3715228Q39999913-E67B0E69-6125-4563-A5F3-49FFD2446A2CQ40014386-BA80664E-505F-4BAD-9CE9-F2D29F185F1DQ40025070-DFCF04DD-F84A-45AF-B237-EF75C2E01AB8Q40339377-B08EF492-0B36-4E0D-AC5E-69285D6B6359Q40512657-10BDAF3E-FEC1-4BE8-B034-22038993A98EQ40954439-4DB53ADA-962D-438C-9EF2-2770FAEFE7C5Q41412002-5D9CEEA6-85F5-44B2-A225-5DBA1A2BC831Q42094443-EACF6823-74B6-47A1-9FC9-AB037E48F3C0Q42202406-CA83480C-6FA7-42ED-9E5C-CD43540C7B84Q42991626-82248342-67B4-432E-80A9-426CAA3981CAQ43196725-90E06C0D-44AC-4189-A77E-177ADFF63338Q43431647-7994A87B-D202-4927-8210-F6586AF9477E
P2860
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
High incidence of prostate can ...... evious negative biopsy series.
@en
High incidence of prostate can ...... evious negative biopsy series.
@nl
type
label
High incidence of prostate can ...... evious negative biopsy series.
@en
High incidence of prostate can ...... evious negative biopsy series.
@nl
prefLabel
High incidence of prostate can ...... evious negative biopsy series.
@en
High incidence of prostate can ...... evious negative biopsy series.
@nl
P2093
P1433
P1476
High incidence of prostate can ...... evious negative biopsy series.
@en
P2093
Alexander Haese
Andreas Erbersdobler
Hartwig Huland
Jochen Walz
Markus Graefen
Pierre I Karakiewicz
Thomas Steuber
Thorsten Schlomm
P304
P356
10.1016/J.EURURO.2006.03.026
P407
P50
P577
2006-03-29T00:00:00Z